Therapeutic advances in cardiac targeted drug delivery: from theory to practice.
Cuican LiMuhammad NaveedKashif DarZiwei LiuMirza Muhammad Faran Ashraf BaigRundong LvMuhammad SaeedChen DingdingYu FengZhou XiaohuiPublished in: Journal of drug targeting (2020)
The most commonly used administration methods in clinics and life are oral administration, intravenous injection, and other systemic administration methods. Targeted administration must be an essential long-term development direction due to the limited availability and a high incidence of systemic side effects. Cardiovascular diseases (CVD) are the leading cause of death all over the world. Targeted drug delivery (TDD) methods with the heart as the target organ have developed rapidly and are diversified. This article reviews the research progress of various TDD methods around the world with a heart as the target organ. It is mainly divided into two parts: the targeting vector represented by nanoparticles and various TDD methods such as intracoronary injection, ventricular wall injection, pericardial injection, and implantable medical device therapy and put forward some suggestions on the development of targeting. Different TDD methods described in this paper have not been widely used in clinical practice, and some have not even completed preclinical studies. Targeted drug delivery still requires long-term efforts by many researchers to realize the true meaning of the heart. HIGHLIGHTS Targeted administration can achieve a better therapeutic effect and effectively reduce the occurrence of adverse reactions. Parenteral administration or medical device implantation can be used for targeted drug delivery. Combined with new dosage forms or new technologies, better-targeted therapy can be achieved. Clinical trials have confirmed the safety and effectiveness of several administration methods.
Keyphrases
- cancer therapy
- drug delivery
- heart failure
- clinical trial
- healthcare
- cardiovascular disease
- clinical practice
- left ventricular
- stem cells
- systematic review
- ultrasound guided
- drug release
- atrial fibrillation
- coronary artery disease
- risk factors
- low dose
- type diabetes
- acute coronary syndrome
- percutaneous coronary intervention
- mesenchymal stem cells
- open label
- bone marrow
- catheter ablation